Independent Director · Royalty Pharma plc (RPRX)

Catherine Engelbert director compensation at Royalty Pharma: $400K

Fiscal year 2025 director compensation for Catherine Engelbert at Royalty Pharma plc. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 10, 2026 (DEF 14A). Open the filing on EDGAR.

Free

Get Catherine Engelbert’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Catherine Engelbert and every company like it: Velarion Intel, free for 3 days, no card →

What they were paid

Royalty Pharma Director Compensation Table · all 3 fiscal years held
In US dollars, as Royalty Pharma reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$150,000$249,891——$399,981
FY2023$150,000$239,770——$389,770
FY2021$150,000$243,813——$393,813

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Royalty Pharma plc DEF 14A filed April 10, 2026, accession 0001140361-26-014239, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Royalty Pharma plc filed document, accession 0001140361-26-014239. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2026.

Get the Royalty Pharma Board Governance Report

$399,981 Catherine Engelbert, FY2025 total director compensation

$500

The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.

Data as of April 10, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

How this board is paid

company policy · FY2025

Royalty Pharma pays directors a $150,000 cash retainer and $250,000 in RSUs.

Committees

FY2025 · as the proxy prints them

Audit

The rest of the Royalty Pharma board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Bonnie Bassler, Ph.DIndependent Director$399,981
Carole Ho, M.DIndependent Director$383,005
David HodgsonIndependent Director$399,981
Elizabeth WeathermanIndependent Director$383,005
Gregory NordenIndependent Director$399,981
Ted Love, M.DLead Independent Director$399,981
Vlad Coric, M.DIndependent Director$462,000

The full Royalty Pharma compensation record

free company brief

This page is one director within Royalty Pharma's record. The company brief lists every named executive and director, each linking to their own page.

Peer companies

named in the Royalty Pharma proxy · each links to its own free brief

Order RPRX

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Board Governance Report